The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

whose NaV1.8 inhibitor suzetrigine (formerly VX-548) has already been filed for approval in the US for two moderate-to-severe acute pain indications, with an FDA decision due by 30th January after ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

Kennedy Jr.'s goals to swap them out with natural alternatives in the U.S. food supply. The FDA's move stops short of the outright ban that had been floated for in Kennedy's "Make America Healthy ...